Sign in
CompletedPhase 3

Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU

Key facts

Who runs it
Ain Shams University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
150 people enrolled
Started
1 Sept 2023
Ended
1 Aug 2025
Type of study
Interventional, 3 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Cerebrolysin
  • amantadine sulfate
Record updated
19 November 2025

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age between 18 and 70 years
  • Clinical diagnosis of head injury with moderate to severe TBI and a Glasgow coma scale (GCS) score of 7-12 at the time of hospital admission
  • Pre-hospital intubation/sedation/paralysis was accepted if the GCS score had been assessed before intubation/sedation/paralysis by trained staff

Who cannot take part

  • History of intracranial interventions as well as ischemic or hemorrhagic stroke
  • Any neurological or non-neurological condition independent from TBI that might influence the functional outcome or other efficacy outcome measures
  • Patient with sever renal impairment (creatinine clearance > 30 ml/ minute)
  • Clear clinical signs of intoxication influencing the evaluation, in the investigator's judgment
  • Patients with penetrating brain injury
  • Pregnancy or lactation

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this interventional study is to Measure the potential benefits of combined administration of cerebrolysin and amantadine sulfate as an add-on therapy to the standard management of patients admitted to the ICU with traumatic brain injury.

The 3 groups in the trial

  • standard of careNo study treatment, for comparison

    patients receiving the standard protocol of management of head injury in the ICU including * Ventilatory support, sedation and analgesia. * Hemodynamic support. * Hyperosmolar therapy. * Early post traumatic seizure prophylaxis. * Nutritional support: will try to start enteral feeds as soon as possible or total parenteral * nutrition will be used in the case of enteral feeding intolerance. * Temperature management: to maintain normothermia * Glycemic control: to maintain a glucose level of \[140 -180 mg/dl\] * Peptic ulcer prophylaxis: * Deep venous thrombosis (DVT) prophylaxis

  • standard of care + CerebrolysinTreatment being tested

    patients receiving the standard protocol of management of head injury in the ICU plus 2 cycles of Cerebrolysin , each cycle 10 days, for total 20 days. From day 1 to day 10: cerebrolysin 50 ml once daily diluted in 250 ml normal saline intravenous infusion over 15 minutes. From day 21-30 : cerebrolysin 20 ml once daily diluted in 250 ml normal saline intravenous infusion over 15 minutes.

    Treatment: Cerebrolysin

  • standard of care + Cerebrolysin + Amantadine sulfateTreatment being tested

    patients receiving the standard protocol of management of head injury in the ICU plus amantadine sulfate at a dose of 100 mg twice daily on the day after randomization, with this dose will be continued for 14 days. The dose will be increased to 150 mg twice daily at week 3 and to 200 mg twice daily at week 4 (total 4 weeks), combined with 2 cycles of Cerebrolysin , each cycle 10 days, for total 20 days. From day 1 to day 10: cerebrolysin 50 ml once daily diluted in 250 ml normal saline intravenous infusion over 15 minutes. From day 21-30 : cerebrolysin 20 ml once daily diluted in 250 ml normal saline intravenous infusion over 15 minutes.

    Treatment: Cerebrolysin and amantadine sulfate

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Impact and Outcomes of Combined Cerebrolysin and Amantadine Sulfate Administration on Management of Patients With Traumatic Brain Injury in the ICU
Record updated
19 November 2025